SKI Market

A+| A| A-|

Indian Indices

Sensex

76,009.70 -479.26
( -0.63%)

Global Indices

Nasdaq

50,600.70 294.03
(0.58%)

Dow Jones

7,494.47 27.75
(0.37%)

Hang Seng

64,932.04 -226.15
(-0.35%)

Nikkei 225

10,466.26 22.79
(0.22%)

Forex

USD-INR

95.61 -0.67
(-0.70%)

EUR-INR

110.97 -0.85
(-0.76%)

GBP-INR

128.43 -0.86
(-0.66%)

JPY-INR

0.60 0.00
(-0.79%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

BSE Focused IT

Industry : Stock Exchanges

BSE Code

ISIN Demat

Book Value()

1196

N.A

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

N.A

21.85

EPS(TTM)

Face Value()

Div & Yield %

100

Back

mphasis ltd

Natco Pharma receives CDSCO approval for launch of Semaglutide in India

Feb 14,2026

Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

76,009.70 -479.26 ( -0.63%)

50,600.70 294.03 (0.58%)

7,494.47 27.75 (0.37%)

64,932.04 -226.15 (-0.35%)

10,466.26 22.79 (0.22%)

95.61 -0.67 (-0.70%)

110.97 -0.85 (-0.76%)

128.43 -0.86 (-0.66%)

0.60 0.00 (-0.79%)